Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD
Open Access
- 1 October 2013
- journal article
- research article
- Published by Elsevier BV in Respiratory Medicine
- Vol. 107 (10), 1538-1546
- https://doi.org/10.1016/j.rmed.2013.06.001
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline
This publication has 22 references indexed in Scilit:
- The Efficacy and Safety of the Novel Long-Acting β 2 Agonist Vilanterol in Patients With COPDSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparisonThorax, 2012
- A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPDRespiratory Medicine, 2012
- Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomesPrimary Care Respiratory Journal, 2012
- Cardiovascular Safety of QVA149, a Combination of Indacaterol and NVA237, in COPD PatientsCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2010
- QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary diseaseThorax, 2010
- The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPDPulmonary Pharmacology & Therapeutics, 2010
- Performance of American Thoracic Society-Recommended Spirometry Reference Values in a Multiethnic Sample of Adults: The Multi-Ethnic Study of Atherosclerosis (MESA) Lung StudySocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2010
- Reducing cholinergic constriction: the major reversible mechanism in COPDEuropean Respiratory Review, 2006
- Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEuropean Respiratory Journal, 2004